ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN wishes from three weeks ago..

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Apr 15, 2021 11:56am

128 Views

Post# 33000822

RE:RE:RE:PMN wishes from three weeks ago..

PMN.to is a long term buy and hold. The new Investors and their debentures expire in 2026. Their goal is to to be listed on the Nasdaq meaning the Stock Price will only rise. Once you notice people are buying and the price is not going up, you can always sell and buy in at a lower point and own more shares. PMN.to is not going anywhere and will contine to strive!

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec